NCT06197217View on ClinicalTrials.gov

Phase III Clinical Study Evaluating the Efficacy and Safety of WPV01 in Patients With Mild/Moderate COVID-19

PHASE3CompletedINTERVENTIONAL
Enrollment

1,350

Participants

Timeline

Start Date

June 14, 2023

Primary Completion Date

August 21, 2023

Study Completion Date

September 20, 2023

Conditions
Mild to Moderate COVID-19
Interventions
DRUG

WPV01

Subjects in the WPV01 group will receive WPV01 600mg orally (200mg, 3 tablets per dose), 3 times daily (TID) for 15 consecutive treatments

DRUG

Placebo

Subjects in the Placebo group will receive WPV01 Placebo orally (3 tablets per dose), 3 times daily (TID) for 15 consecutive treatments

Trial Locations (1)

100029

China Japan Friendship Hospital, Beijing

All Listed Sponsors
lead

Westlake Pharmaceuticals (Hangzhou) Co., Ltd.

INDUSTRY

NCT06197217 - Phase III Clinical Study Evaluating the Efficacy and Safety of WPV01 in Patients With Mild/Moderate COVID-19 | Biotech Hunter | Biotech Hunter